P279 Post-authorization safety study of hyaluronidase-facilitated subcutaneous immunoglobulin 10% treatment in patients with primary immunodeficiency diseases

Autor:	R. Honigberg, D. McNeil, Arye Rubinstein, Heinz Leibl, Christopher J. Rabbat, Richard L. Wasserman, H. Wedner, T. Bridges, Leman Yel, Raffi Tachdjian
Rok vydání:	2017
Předmět:	Pulmonary and Respiratory Medicine business.industry Immunology Authorization Subcutaneous immunoglobulin medicine.disease Hyaluronidase Primary immunodeficiency medicine Immunology and Allergy In patient business medicine.drug
Zdroj:	Annals of Allergy, Asthma & Immunology. 119:S71
ISSN:	1081-1206
DOI:	10.1016/j.anai.2017.08.195
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::06f64188cd3bb34a27d8e00a875fb4ea https://doi.org/10.1016/j.anai.2017.08.195 Zobrazit plný text záznamu